Search results for: 'tech n tran crayvxn rerio'
- Product Name
- Organism
- Tag (Tag info)
- Expression Host (Source)
- Did you mean
- tert n tran crayvxn rerio
- tech n tree crayvxn rerio
- Related search terms
- technician A says that part-time four wheel drive does not use a transfer cas. technician b says that a viscous clutch is locate
- tran and swine goods river ca
- tran n tick crayvxn rerio
- tran n thiol crayvxn rerio
- tran n type crayvxn rerio
- 
                Anti-Human HER2 (Margetuximab)HumanN/ACHOVarious size from 1 mg to 164 mg available. Please inquiry us first for the price and availablity. 
- 
                Anti-Human LOXL2 (Simtuzumab)HumanN/ACHOVarious size from 1 mg to 172 mg available. Please inquiry us first for the price and availablity. 
- 
                Anti-Human MSLN (Amatuximab)HumanN/ACHOVarious size from 1 mg to 173 mg available. Please inquiry us first for the price and availablity. 
- 
                Anti-Human FcRn (Nipocalimab)HumanN/ACHOVarious size from 1 mg to 174 mg available. Please inquiry us first for the price and availablity. 
- 
                Anti-Human FcRn (Rozanolixizumab)HumanN/ACHOVarious size from 1 mg to 175 mg available. Please inquiry us first for the price and availablity. 
- 
                Anti-Human CD20 (Rituximab)HumanN/ACHOVarious size from 1 mg to 176 mg available. Please inquiry us first for the price and availablity. 
- 
                Anti-Human CD137 (Urelumab)HumanN/ACHOVarious size from 1 mg to 177 mg available. Please inquiry us first for the price and availablity. 
- 
                Anti-Human TACSTD2 (Sacituzumab)HumanN/ACHOVarious size from 1 mg to 179 mg available. Please inquiry us first for the price and availablity. 
- 
                Anti-Human BAFF (Belimumab)HumanN/ACHOVarious size from 1 mg to 182 mg available. Please inquiry us first for the price and availablity. 
- 
                Anti-Human PD1 (Camrelizumab)HumanN/ACHOVarious size from 1 mg to 185 mg available. Please inquiry us first for the price and availablity. 
